We read with interest the editorial by Barry and colleagues on their perspectives of the planned NHS Diabetes Prevention Programme (NHS DPP). Whilst we agree on some issues, we feel there are a number of errors regarding their interpretation of the evidence and that the projected relevance to the NHS has been underestimated.
The authors make two incorrect assertions with regards to the prevalence of non-diabetic hyperglycaemia and risk score use.
Firstly, the use of HbA1c to identify non-diabetic hyperglycaemia does not, as stated, identify twice as many people compared to oral glucose tolerance test (OGTT) criteria. The prevalence of impaired fasting glucose and/or impaired gl